Non-Alcoholic Fatty Liver Disease (NAFLD), a metabolic liver disorder characterized by hepatic steatosis, chronic inflammation, and risk of fibrosis and cirrhosis. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Participants will receive daily oral supplementation with 2 capsules of naringenin (each capsule containing 200 mg naringenin + 300 mg starch) for 3 months. Capsules will be taken ever
Sponsors
Shahre-kord University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age 20–65 years Body mass index between 25 and 35 kg/m² Diagnosis of NAFLD confirmed by ultrasound Written informed consent
Exclusion criteria
Exclusion criteria: Use of herbal supplements, antioxidants, omega-3, probiotics, or multivitamins in the past three months Use of NSAIDs, antibiotics, corticosteroids, or weight-loss medications Pregnancy or breastfeeding Menopause Substance or alcohol abuse Liver pathologic disorders, viral hepatitis, or liver transplantation Diabetes, gastrointestinal diseases, organ failure, thyroid disorders, kidney diseases, autoimmune disorders Severe psychiatric disorders or cardiovascular events in the past three months Any malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum C-reactive protein (CRP) level in patients with non-alcoholic fatty liver disease (NAFLD). Timepoint: Baseline (before intervention) and at 3 months after daily naringenin supplementation. Method of measurement: Serum CRP measured using standard laboratory immunoassay kits. | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory factor related to immune response. Timepoint: Baseline and 12-week follow-up. Method of measurement: Serum levels measured using standard enzyme-linked immunosorbent assay kits.;Second inflammatory factor related to immune response. Timepoint: Baseline and 12-week follow-up. Method of measurement: Serum levels measured using standard enzyme-linked immunosorbent assay kits.;Low-density lipoprotein. Timepoint: Baseline and 12-week follow-up. Method of measurement: Measured using standard enzymatic colorimetric laboratory kits.;High-density lipoprotein. Timepoint: Baseline and 12-week follow-up. Method of measurement: Measured using standard enzymatic colorimetric laboratory kits.;Participant adherence. Timepoint: Midpoint and end of study. Method of measurement: Counting remaining capsules and calculating adherence percentage.;Adverse events. Timepoint: Throughout the intervention period. Method of measurement: Self-reported events recorded at each follow-up visit and via structured questionnaires. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Karami horestani
Shahre-kord University of Medical Sciences
Outcome results
None listed